A clinical trial has revealed that lung cancer cells with strong E-cadherin expression exhibit a significantly longer time to progression after EGFR-tyrosine kinase inhibitor (EGFR-TKI) treatment 9. The gene discussed is EGFR; the disease is lung cancer.